[Skip to Content]
[Skip to Content Landing]
April 27, 2005

Arthritis Medications and Cardiovascular Events

JAMA. 2005;293(16):1975-1977. doi:10.1001/jama.293.16.1976-a

To the Editor: The US Food and Drug Administration recently announced the premature discontinuation of ADAPT due to an apparent increase in adverse cardiovascular events associated with naproxen.1 Because previous reports have shown naproxen to have a cardioprotective effect, this finding was unexpected and has caused a considerable amount of confusion among practitioners and the public.2

First Page Preview View Large
First page PDF preview
First page PDF preview